drugset / Trial / NCT00119691

Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction

NCT00119691

Phase 2 Completed 34 enrolled Brigham and Women's Hospital Scios, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The researchers hypothesize that the addition of nesiritide to standard therapy will prevent worsening of renal function in patients admitted to the hospital with decompensated heart failure and renal dysfunction relative to standard therapy alone.

Timeline

Start
2003-04
Primary completion
2005-11
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Nesiritide Protein / enzyme biologic 0.03 ug/kg